3-Bromo-4-fluoropyridine (cas: 116922-60-2) belongs to pyridine derivatives. Pyridine’s the lone pair does not contribute to the aromatic system but importantly influences the chemical properties of pyridine, as it easily supports bond formation via an electrophilic attack. Many analogues of pyridine are known where N is replaced by other heteroatoms . Substitution of one C–H in pyridine with a second N gives rise to the diazine heterocycles (C4H4N2), with the names pyridazine, pyrimidine, and pyrazine.SDS of cas: 116922-60-2
Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3-a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaV1.7 Inhibitors for the Treatment of Pain was written by Focken, Thilo;Chowdhury, Sultan;Zenova, Alla;Grimwood, Michael E.;Chabot, Christine;Sheng, Tao;Hemeon, Ivan;Decker, Shannon M.;Wilson, Michael;Bichler, Paul;Jia, Qi;Sun, Shaoyi;Young, Clint;Lin, Sophia;Goodchild, Samuel J.;Shuart, Noah G.;Chang, Elaine;Xie, Zhiwei;Li, Bowen;Khakh, Kuldip;Bankar, Girish;Waldbrook, Matthew;Kwan, Rainbow;Nelkenbrecher, Karen;Karimi Tari, Parisa;Chahal, Navjot;Sojo, Luis;Robinette, C. Lee;White, Andrew D.;Chen, Chien-An;Zhang, Yi;Pang, Jodie;Chang, Jae H.;Hackos, David H.;Johnson, J. P.;Cohen, Charles J.;Ortwine, Daniel F.;Sutherlin, Daniel P.;Dehnhardt, Christoph M.;Safina, Brian S.. And the article was included in Journal of Medicinal Chemistry in 2018.SDS of cas: 116922-60-2 This article mentions the following:
The sodium channel NaV1.7 has emerged as a promising target for the treatment of pain based on strong genetic validation of its role in nociception. In recent years, a number of aryl and acyl sulfonamides have been reported as potent inhibitors of NaV1.7, with high selectivity over the cardiac isoform NaV1.5. Herein, we report on the discovery of a novel series of N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)methanesulfonamides as selective NaV1.7 inhibitors. Starting with the crystal structure of an acyl sulfonamide, we rationalized that cyclization to form a fused heterocycle would improve physicochem. properties, in particular lipophilicity. Our design strategy focused on optimization of potency for block of NaV1.7 and human metabolic stability. Lead compounds I (R1 = cPr, R2 = Me), I (R1 = cPr, R2 = cPr) (GNE-131), and II showed excellent potency, good in vitro metabolic stability, and low in vivo clearance in mouse, rat, and dog. Compound I (R1 = cPr, R2 = cPr) also displayed excellent efficacy in a transgenic mouse model of induced pain. In the experiment, the researchers used many compounds, for example, 3-Bromo-4-fluoropyridine (cas: 116922-60-2SDS of cas: 116922-60-2).
3-Bromo-4-fluoropyridine (cas: 116922-60-2) belongs to pyridine derivatives. Pyridine’s the lone pair does not contribute to the aromatic system but importantly influences the chemical properties of pyridine, as it easily supports bond formation via an electrophilic attack. Many analogues of pyridine are known where N is replaced by other heteroatoms . Substitution of one C–H in pyridine with a second N gives rise to the diazine heterocycles (C4H4N2), with the names pyridazine, pyrimidine, and pyrazine.SDS of cas: 116922-60-2
Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem